Biotech Wiz

[Biotech Wiz @Bio_Wizard_Oz]

$ARDX

First Post.

Using my advanced AI algorithm I have identified what I believe to be the most likely next Pharmaceutical company to be acquired.

I will post my Second after this one completes.

Probability: 79% < 60 Days.

[Biotech Wiz @Bio_Wizard_Oz]

@ardelyx Zydus. September?

[Biotech Wiz @Bio_Wizard_Oz]

@MarioNawfal Fuck Shake Shack

Fuck Chicken Salad Chick

NEVER patronize anyone that asks for tips for takeout.

[Biotech Wiz @Bio_Wizard_Oz]

$ARDX

Start Thursday ER.

Start adding you animals!

Greatest tweet crystal ball:

[Biotech Wiz @Bio_Wizard_Oz]

$ARDX

$12 by December 31.

Record revenue Earnings Report blow out.

[Biotech Wiz @Bio_Wizard_Oz]

@3YearLetterman

[Biotech Wiz @Bio_Wizard_Oz]

@adamfeuerstein $CAPR

[Biotech Wiz @Bio_Wizard_Oz]

@adamfeuerstein @pharmalot @elaineywchen Deceptive? You decide. $NWBO

[BioPharm_the_Magnificent @crypto_biotech]

Adam Feuerstein at STAT News has made a career out of relentlessly attacking $NWBO.

The “objective journalist” label doesn’t hold up when you hear what actual biotech professionals and investors say about your coverage once they’re off the record at conferences.

You can publish whatever narrative you want online. But reputation is what people say about you when you’re not in the room.

The mask tends to slip when the professionals start talking candidly. 🤡

[Biotech Wiz @Bio_Wizard_Oz]

$ARDX

$12 by December 31.

Record revenue Earnings Report blow out.

[Andrii Martyniuk @AndriiMart1]

$ARDX #Xphozan is proving its clinical significance. The path to $750M revenue is looking increasingly de-risked following new data.
​Clinical breakdown:
-​ Pill burden slashed by 73%
- ​45.6% of patients off binders entirely
- ​Broad-spectrum efficacy across all subgroups

[Biotech Wiz @Bio_Wizard_Oz]

$ARDX

One cannot read this enough nor own enough shares.

[Biotech Wiz @Bio_Wizard_Oz]

$ARDX

[Flash by StockSentinel.ai @SentinelFlash]

The market just threw $ARDX out after yesterday’s Medicare ruling—but institutional money is treating the legal defeat as a sideshow. While retail panics over court drama, they are missing a 95% gross margin asset on a straight line to $1B. Here is the non-obvious math behind this massive valuation disconnect. 📊 #Biotech

https://t.co/ufoWcREKXw

[Biotech Wiz @Bio_Wizard_Oz]

@ShermanPeck3 @Dogsrgreat2 @LamarMK Thanks for paying for the blue checkmark. I own $TSLA stock and on behalf of every FSD owner…

[Biotech Wiz @Bio_Wizard_Oz]

$ARDX BO imminent?

Claude: 14% ONLY 3 days since entry already passed its 1-month $7 target.

Strong ‘clean prints’ in the book.

Swap (6.3% weight) delivering fast on M&A catalyst thesis.

Portfolio all-time ~+7%. Track live: https://t.co/xwu9MdbfoZ
#ClaudePortfolio $ARDX”

[Biotech Wiz @Bio_Wizard_Oz]

$ARDX

When your Biotech has been left for dead (like a CRL) and it gets a Buyout- this is what shareholders will look like:

[Breaking911 @Breaking911]

WATCH: Video of Cherie DeVaux, trainer of Golden Tempo, shows her reaction to winning the Kentucky Derby

[Biotech Wiz @Bio_Wizard_Oz]

$ARDX

We will see earnings captivate and produce 20% share price if not more increase.

Tag China income or don’t- boom.

(My odds for favorable lawsuit rendering have gone up. Don’t tell anyone. You heard it here first)

[Biotech Wiz @Bio_Wizard_Oz]

$ARDX

Beat coming.

More news imminent.

$8 plus.

Bookmark.

[Biotech Wiz @Bio_Wizard_Oz]

$ARDX

Nice.

But what happens any day is imminent. I am shocked it’s taken this long.

Here is a clue:

A. Zydus-like
B. CMS related
C. Other

Bonus- FACT: Earnings/ Scripts will exceed.

[Frank @justfactstruth]

$ARDX Full article
https://t.co/rDmC6TtqCd

On March 10, 2026, the first prescription in China for Tenapanor Hydrochloride Tablets (trade name: Ventira®), a first-in-class innovative drug licensed by Fosun Pharma, was issued by Professor Zuo Li, Director of the Department of Nephrology at Peking University People's Hospital. As the world's first and currently only approved phosphate absorption inhibitor, the commercial launch of Tenapanor Hydrochloride Tablets marks a disruptive breakthrough in the treatment of hyperphosphatemia, bringing a new treatment option to dialysis patients with chronic kidney disease (CKD) in China.

Excellent clinical value, reshaping the treatment landscape of hyperphosphatemia
Hyperphosphatemia is one of the most common complications in dialysis patients with chronic kidney disease and a key risk factor for increased cardiovascular events and all-cause mortality. However, traditional treatment regimens have long faced three major challenges: difficulty in achieving target levels, heavy burden, and poor adherence. The rate of achieving target serum phosphorus levels has remained at a low level for a long time, patients need to take large doses of phosphate binders daily, and gastrointestinal adverse reactions occur frequently, seriously affecting their quality of life and confidence in treatment.

Tenapanor hydrochloride tablets, as the world's first and currently only approved phosphorus absorption inhibitor, overcome traditional limitations in mechanism—by specifically inhibiting intestinal NHE3, blocking paracellular pathway phosphorus absorption, and achieving phosphorus reduction targets at the source. Clinical studies show that the rate of achieving target serum phosphorus levels is significantly improved after using tenapano. It also offers multiple benefits such as small tablet size, low oral burden, and improved constipation, truly providing dual protection for patients' "therapeutic effect" and "quality of life."

Professor Zuo Li, Director of the Department of Nephrology at Peking University People's Hospital and the principal investigator of the Phase III clinical trial of tenapanol hydrochloride tablets in China, stated, "Tenapano hydrochloride tablets, as the world's first phosphorus absorption inhibitor, overcome the limitations of traditional phosphate binders in its mechanism of action, blocking phosphorus absorption at the source and opening up a new path for the treatment of hyperphosphatemia, bringing tangible long-term prognostic improvements to patients. Peking University People's Hospital served as the principal investigator for the Phase III clinical trial of this drug in China, and we have seen the efficacy data and safety performance of tenapanol hydrochloride tablets. I have high expectations for the clinical application of this drug." From a clinical perspective, it is hoped that this drug can effectively address the core pain points in the management of hyperphosphatemia in dialysis patients in my country, such as limited efficacy, low target achievement rate, and excessive pill burden. This will help improve the overall management level of hyperphosphatemia in my country, reduce the risk of cardiovascular and all-cause mortality, and effectively improve the quality of life and long-term prognosis of dialysis patients. Encouragingly, this innovative drug, with both domestic and international clinical evidence, has been successfully included in the national medical insurance program and completed all the necessary procedures for clinical implementation. The first prescription was recently issued, injecting new momentum into the standardized management of hyperphosphatemia in CKD patients in my country.

[Biotech Wiz @Bio_Wizard_Oz]

$ARDX

Happening. In-progress.

[Biotech Wiz @Bio_Wizard_Oz]

$ARDX

≈APRIL 15.

Coming.

[Biotech Wiz @Bio_Wizard_Oz]

$ARDX

Look for surprise PR by tax day.

Not an “if” but “OMG”.

Following the small breadcrumbs that airline tracking websites provide clues for.

Why April 15? Because June 1 the sand is at the bottom of the hourglass.

[Biotech Wiz @Bio_Wizard_Oz]

$ARDX

Look for surprise PR by tax day.

Not an “if” but “OMG”.

Following the small breadcrumbs that airline tracking websites provide clues for.

Why April 15? Because June 1 the sand is at the bottom of the hourglass.

[Biotech Wiz @Bio_Wizard_Oz]

$ARDX

1. IBSRELA exploding: $274M in 2025 (+73%), guided $410-430M in 2026.

2. XPHOZAH steady: $104M in 2025, guided $110-120M in 2026.

3. 2026 total revenue guidance
$520-550M w path to profitability.

4. Patents locked to 2042, protecting $1B+ peak potential.

5. Pipeline.

[Biotech Wiz @Bio_Wizard_Oz]

$ARDX

March Madness starts today.